Promising stomach cancer combo trial pulled before enrolling a single patient
NCT ID NCT06967987
First seen Sep 30, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study aimed to test whether adding the targeted drug bemarituzumab to standard FLOT chemotherapy could improve outcomes for people with resectable stomach or gastroesophageal junction cancer that overexpresses FGFR2b. The trial was designed for adults with stage cT2-T4a or node-positive disease. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC AND GASTRO-OESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU de Brest
Brest, 29609, France
-
CHU de Poitiers
Poitiers, 86021, France
-
CHU de Rennes
Rennes, 35000, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Gustave Roussy
Villejuif, 94805, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Paoli Calmette
Marseille, 13273, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France
-
Institut de Cancérologie de l'Ouest
Angers, 49055, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, 44805, France
Conditions
Explore the condition pages connected to this study.